AI Article Synopsis
- * The review highlights how metabolic changes can affect both immune cells and tumor growth, while cellular aging can limit anti-cancer responses and make treatments less effective.
- * It suggests that targeting the metabolism of immune cells and encouraging aging in tumor cells could be potential treatment strategies, though further research is necessary to find specific targets and improve treatment results for patients.
Article Abstract
Ovarian cancer is a highly malignant gynecological cancer influenced by the immune microenvironment, metabolic reprogramming, and cellular senescence. This review provides a comprehensive overview of these characteristics. Metabolic reprogramming affects immune cell function and tumor growth signals. Cellular senescence in immune and tumor cells impacts anti-tumor responses and therapy resistance. Targeting immune cell metabolism and inducing tumor cell senescence offer potential therapeutic strategies. However, challenges remain in identifying specific targets and biomarkers. Understanding the interplay of these characteristics can lead to innovative therapeutic approaches. Further research is needed to elucidate mechanisms, validate strategies, and improve patient outcomes in ovarian cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702973 | PMC |
| http://dx.doi.org/10.3389/fendo.2023.1265525 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.
Expert Opin Drug Saf
January 2025
Department of Obstetrics, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objectives: Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.
Methods: This study performed a retrospective analysis using real-world data extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Innovative landscapes in intraperitoneal therapy of ovarian cancer.
Drug Deliv Transl Res
January 2025
Amrita School of Nanosciences & Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
Epithelial ovarian cancer is the most prevalent gynecological malignancy, characterized by high mortality rates due to its late-stage diagnosis and frequent recurrence. The current standard of care for ovarian cancer is a combination of debulking surgery followed by the conventional mode of chemotherapy. Despite significant advances in therapeutic modalities, the overall survival rate of EOC continues to be poor, mainly because low concentrations of the chemotherapeutics reach the peritoneum, which is the primary site of ovarian cancer, leading to disease relapse.
View Article and Find Full Text PDFLeukemic cells infiltrate the ovaries without damaging ovarian reserve in an acute myeloid leukemia mouse model.
Endocrinology
January 2025
Olson Center for Women's Health, Department of Obstetrics and Gynecology, College of Medicine, University of Nebraska Medical Center, Omaha, NE.
Leukemia is one of the most common cancers in prepubertal girls and adolescents, with advances improving survival rates. However, treatments like chemotherapy and radiation are highly gonadotoxic, often causing ovarian insufficiency, early menopause, infertility, and endocrine disorders. Fertility preservation for young female cancer patients, especially prepubertal girls without mature germ cells, relies heavily on ovarian tissue cryopreservation.
View Article and Find Full Text PDFPRDX6 Prevents NNMT Ubiquitination and Degradation as a Nonenzymatic Mechanism to Promote Ovarian Cancer Progression.
Adv Sci (Weinh)
January 2025
West China School of Basic Medical Sciences & Forensic Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
Cancer cells cope with oxidative stress for their proliferation and metastasis by equipping antioxidant systems, among which the antioxidant enzymes peroxiredoxins (PRDXs) play crucial roles. However, whether PRDXs exhibit nonenzymatic functions remains unclear. Here, it is shown that the 1-cysteine PRDX (PRDX6) upregulates nicotinamide N-methyltransferase (NNMT) to promote the growth and metastasis of ovarian cancer cells, independently of PRDX6's enzymatic activities.
View Article and Find Full Text PDFOvarian function in adolescents and young adults undergoing cancer treatment: biochemical and ultrasound marker analysis.
Endocr Connect
January 2025
S Stagi, Meyer Children's Hospital IRCCS, Florence, Italy.
Objective: Gonadal dysfunction is a major late complication after cancer diagnosis and treatment. We aimed to study the prevalence of premature ovarian insufficiency (POI) and the potential reduction of ovarian reserve in a cohort of adolescent and young adult (AYA) patients undergoing cancer treatments, evaluating ovarian function and reserve markers. We also aimed to analyze how these markers are related to each other and to treatment-related risk factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!